SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to widespread discussion around year-end tax loss selling and persistent selling from early investors, which is currently driving significant downward pressure. Community sentiment remains sharply divided, with some seeing current levels as a compelling buying opportunity given the company's profitability and growth, while others emphasize ongoing dilution concerns and a challenging market backdrop.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to the recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in over four decades. The community is actively discussing its potential to alleviate GLP-1 induced nausea, viewing this as a significant market opportunity and a catalyst for potential buyouts. While some initially expressed mixed reactions to price action, many believe the stock's long-term value and additional pipeline catalysts are not yet fully reflected.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a contentious and repeatedly postponed shareholder vote on increasing authorized shares, sparking intense debate over its future funding and growth strategy. Bulls anticipate significant, often classified, government contracts and strategic benefits from the Ask Sage acquisition, viewing current price movements as short-term manipulation. Conversely, skeptics express frustration with management, citing a lack of tangible contract announcements and fearing potential dilution, leading to a polarized community discussion.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending amidst intense speculation regarding an unconfirmed FDA decision on its relacorilant drug for Cushing's Syndrome, with community chatter divided between rumored rejection causing panic selling and calls to buy the dip. The immediate uncertainty around this key pipeline asset, alongside its existing revenue-generating drug Korlym and other promising indications like ovarian cancer, fuels a volatile debate among investors.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing heightened volatility as the CME implements multiple margin requirement hikes, fueling intense community debate over market manipulation. Many perceive these actions as a concerted effort to suppress prices and liquidate leveraged positions, especially with reported disparities between paper and physical silver values globally. Despite calls of a "rigged game" and comparisons to past crashes, a strong bullish contingent anticipates a significant long-term rally driven by robust industrial demand and ongoing concerns about supply.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing a surge in attention fueled by high expectations for its upcoming earnings report, with the community anticipating strong revenue growth driven by its high-margin drug Recorlev. Investors are also keenly focused on the company's pathway to sustained profitability and the long-term potential of its pipeline, particularly the promising XP-8121, which analysts believe could achieve blockbuster status. This positive outlook is supported by recent analyst target upgrades and a perceived de-risked profile, positioning Xeris for significant growth within the biopharma sector.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to high anticipation for upcoming FDA decisions regarding AXS-05 for Alzheimer's agitation and AXS-12 for narcolepsy, with the community optimistic about potential approvals. This regulatory excitement is complemented by strong, consistent prescription growth and expanding market access for its major depressive disorder treatment, Auvelity. Investors are keenly focused on these catalysts and the company's broader CNS pipeline, despite some impatience with communication around timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Renesas Electronics shares fall as major supplier Wolfspeed files for bankruptcy

Investing.com-- Shares of  Renesas Electronics Corp  (TYO:6723) fell in Tokyo trade on Tuesday after Wolfspeed Inc (NYSE:WOLF), a major U.S. supplier of the company, filed for bankruptcy and outlined plans to slash its debt commitments. 

Shares of Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) fell by more than 1% on Monday following a report by Edgewater Research suggesting that performance problems with Monolithic Power's (<a class="mention" data-mention="$MPWR" data-symbol-id="MPWR" href="https://stocktwits.com/symbol/MPWR" target="_blank">$MPWR</a>) components could reduce or even eliminate the company's role in Nvidia's next-generation Blackwell processors.&nbsp;As a result, Monolithic Power’s stock dropped sharply by over 20%.The report claimed that while Nvidia will honor existing orders, it has canceled much of Monolithic's future business and redirected orders to other suppliers, Renesas Electronics Corp. (<a class="mention" data-mention="$RNECY" data-symbol-id="RNECY" href="https://stocktwits.com/symbol/RNECY" target="_blank">$RNECY</a>) and Infineon Technologies AG (<a class="mention" data-mention="$IFNNY" data-symbol-id="IFNNY" href="https://stocktwits.com/symbol/IFNNY" target="_blank">$IFNNY</a>).&nbsp;"We hear NVDA will go through their confirmed orders to MPWR for the next few quarters, but we hear NVDA has canceled half of MPWR's backlog, cutting all of their unconfirmed orders," the report said.Both companies saw their stock prices rise by over 3% in mid-day trading on Monday.Issues with Monolithic Power’s voltage regulator module and power management IC&nbsp;"appear likely to severely limit or eliminate"&nbsp;the company’s role in the production of Nvidia’s Blackwell chips, according to Edgewater Research.&nbsp;Renesas and Infineon are set to take over key components for Nvidia's upcoming chips, with Renesas stepping in for the B200 allocation and Infineon handling the GB200 allocation.Both companies have received urgent orders in recent weeks, according to Edgewater’s report.Despite these concerns, Deutsche Bank remains skeptical that Monolithic will lose all of its Nvidia business.&nbsp;The brokerage argues that the strong relationship and incumbent position Monolithic holds with Nvidia makes it unlikely that the performance issues are as severe as reported.&nbsp;However, if the claims prove accurate, Monolithic could see up to 15% of its revenue at risk.Deutsche Bank has maintained its ‘Buy’ rating on Monolithic Power’s stock with a price target of $900.<figure class="image"><img style="aspect-ratio:1283/291;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_11_113659_3e2c467748.png" alt="Screenshot 2024-11-11 113659.png" width="1283" height="291"><figcaption>Nvidia Sentiment and Message Volume on Nov 9 as of 11:35 a.m. ET | Source: Stocktwits</figcaption></figure>Retail sentiment around Nvidia has flipped to ‘bullish’ (58/100) despite the dip in stock value.&nbsp;Nvidia’s stock hit a new all-time high on Friday after joining the Dow Jones Industrial Average ($DJIA).&nbsp;<stembedurl>https://stocktwits.com/TheProphetOfProfit/message/591996154</stembedurl>As Nvidia gears up to report its third-quarter results on Nov. 20, analysts are largely optimistic. Wall Street expects earnings of $0.74 per share on $32.96 billion in revenue, according to Stocktwits data.Morgan Stanley raised its price target on Nvidia to $160 from $150, maintaining an ‘Overweight’ rating on Monday.&nbsp;While the brokerage anticipates a strong quarterly showing, it suggests the bigger upgrades may come later, as Nvidia’s supply remains tight for Blackwell and partly for H200 processors.Piper Sandler also lifted its price target, going from $140 to $175, citing Nvidia’s “dominant positioning” in AI accelerators and the anticipated Blackwell launch.&nbsp;With Nvidia’s stock already up over 200% this year, investors will be closely watching the company's Q3 performance and outlook, especially given its strategic moves in AI and chip technology.For updates and corrections email newsroom@stocktwits.com.Read more:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-stock-all-time-high-after-dow-jones-entry/cJ44fBdRaM">NVIDIA Stock Rallies To Record High After Dow Entry, Retail Sentiment Cools From Peak Levels</a>

Nvidia's is scheduled to report its third-quarter results on Nov. 20. | Source: Will Buckner via Flickr

Nvidia Stock Dips As Monolithic Power Crashes On Concerns of Supplier Allocation For Blackwell AI Chips: Retail Focuses On Earnings

A report by Edgewater Research cited issues with Monolithic Power’s voltage regulator module and power management IC as the reason behind the company getting edged out of the production of Nvidia’s Blackwell chips. 

Equity

A report by Edgewater Research cited issues with Monolithic Power’s voltage regulator module and power management IC as the reason behind the company getting edged out of the production of Nvidia’s Blackwell chips. 


Renesas Electronics Corp. engages in the design, research, development, manufacture, sale and servicing of semiconductor products. Its products include 'in-vehicle control' semiconductors that control engines and car bodies, and 'car information' semiconductors for in-vehicle information such as navigation systems. It also provides semiconductors for industrial equipment, home appliances, and network infrastructure. The company was founded on November 1, 2002 and is headquartered in Tokyo, Japan.

RNECY
Renesas Electronics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RNECY News

RNECYRenesas Electronics Corp